Lyell Wealth Management LP Acquires 72 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Lyell Wealth Management LP grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,123 shares of the company’s stock after acquiring an additional 72 shares during the period. Lyell Wealth Management LP’s holdings in IDEXX Laboratories were worth $8,733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. TimesSquare Capital Management LLC grew its position in shares of IDEXX Laboratories by 31.9% during the 4th quarter. TimesSquare Capital Management LLC now owns 193,516 shares of the company’s stock valued at $80,007,000 after acquiring an additional 46,857 shares during the period. Waycross Partners LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $13,411,000. Cardinal Capital Management lifted its stake in shares of IDEXX Laboratories by 0.3% during the 4th quarter. Cardinal Capital Management now owns 13,954 shares of the company’s stock valued at $5,769,000 after buying an additional 35 shares in the last quarter. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $38,000. Finally, Venturi Wealth Management LLC lifted its stake in shares of IDEXX Laboratories by 465.3% during the 4th quarter. Venturi Wealth Management LLC now owns 571 shares of the company’s stock valued at $236,000 after buying an additional 470 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of analyst reports. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Morgan Stanley lowered their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,330 shares of company stock worth $6,161,276. 2.18% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Up 1.0 %

Shares of NASDAQ IDXX opened at $449.06 on Wednesday. The firm’s 50-day moving average price is $430.82 and its 200-day moving average price is $452.56. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $36.77 billion, a price-to-earnings ratio of 42.09, a P/E/G ratio of 3.35 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.